Inventor · disambiguated record

Harpreet Singh

Also filed as: SINGH HARPREET

505 granted patents·99 pending applications·4,468 citations·filing 2006–2025

99Inventor score

Technology areasG01N A61P A61K C07K C12N

Files withIMMATICS BIOTECHNOLOGIES GMBH586 WEINSCHENK TONI7 SINGH HARPREET5 FRITSCHE JENS3 immatics biotechnology GmbH2

Top patents by PatentIndex Score

604 records

0199US11890334B2Personalized immunotherapy against several neuronal and brain tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Feb 6, 2024·8 cites·20 claims
0299US11826409B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Nov 28, 2023·6 cites·20 claims
0399US11786584B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Oct 17, 2023·4 cites·20 claims
0499US11759507B2Personalized immunotherapy against several neuronal and brain tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Sep 19, 2023·9 cites·20 claims
0599US11618774B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Apr 4, 2023·6 cites·20 claims
0699US11607446B2Personalized immunotherapy against several neuronal and brain tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Mar 21, 2023·14 cites·20 claims
0799US11529401B2Personalized immunotherapy against several neuronal and brain tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Dec 20, 2022·14 cites·20 claims
0899US11529400B1Personalized immunotherapy against several neuronal and brain tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Dec 20, 2022·14 cites·20 claims
0999US11524059B2Personalized immunotherapy against several neuronal and brain tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Dec 13, 2022·14 cites·20 claims
1099US11498948B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Nov 15, 2022·4 cites·20 claims
1199US11479589B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Oct 25, 2022·4 cites·20 claims
1299US11466072B2Peptides and combination of peptides for use in immunotherapy against various tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Oct 11, 2022·17 cites·20 claims
1399US11459371B2Peptides and combination of peptides for use in immunotherapy against various tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Oct 4, 2022·6 cites·22 claims
1499US11440947B2Peptides and combination of peptides for use in immunotherapy against various tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Sep 13, 2022·6 cites·20 claims
1599US11434274B2Peptides and combination of peptides for use in immunotherapy against various tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Sep 6, 2022·6 cites·20 claims
1699US11434273B2Peptides and combination of peptides for use in immunotherapy against various tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Sep 6, 2022·6 cites·20 claims
1799US11414472B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Aug 16, 2022·3 cites·20 claims
1899US11414470B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Aug 16, 2022·6 cites·20 claims
1999US11407808B2Peptides and combination of peptides for use in immunotherapy against various tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Aug 9, 2022·12 cites·20 claims
2099US11407807B2Peptides and combination of peptides for use in immunotherapy against various tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Aug 9, 2022·17 cites·20 claims
2199US11407798B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Aug 9, 2022·6 cites·20 claims
2299US11407810B2Peptides and combination of peptides for use in immunotherapy against various tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Aug 9, 2022·6 cites·20 claims
2399US11407809B2Peptides and combination of peptides for use in immunotherapy against various tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Aug 9, 2022·6 cites·20 claims
2499US11401319B2Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Aug 2, 2022·3 cites·20 claims
2599US11370817B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Jun 28, 2022·6 cites·20 claims
2699US11365234B2Peptides and combination of peptides for use in immunotherapy against various tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Jun 21, 2022·12 cites·20 claims
2799US11365235B2Peptides and combination of peptides for use in immunotherapy against various tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Jun 21, 2022·6 cites·20 claims
2899US11352401B1Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Jun 7, 2022·4 cites·20 claims
2999US11332512B2Peptides and combination of peptides for use in immunotherapy against various tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted May 17, 2022·12 cites·20 claims
3099US11324812B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted May 10, 2022·11 cites·20 claims
3199US11298404B2Immunotherapy against several tumors including gastrointestinal and gastric cancerIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Apr 12, 2022·14 cites·20 claims
3299US11292821B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Apr 5, 2022·5 cites·20 claims
3399US11279741B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Mar 22, 2022·7 cites·20 claims
3499US11279740B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Mar 22, 2022·4 cites·20 claims
3599US11273200B2Immunotherapy against several tumors including gastrointestinal and gastric cancerIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Mar 15, 2022·15 cites·20 claims
3699US11261224B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Mar 1, 2022·5 cites·20 claims
3799US11208434B2Immunotherapy against several tumors including neuronal and brain tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Dec 28, 2021·14 cites·20 claims
3899US11155597B2Relaxin1 derived peptides for use in immunotherapyIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Oct 26, 2021·17 cites·20 claims
3999US11136352B2Immunotherapy against several tumors including neuronal and brain tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Oct 5, 2021·11 cites·20 claims
4099US11123370B2Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Sep 21, 2021·4 cites·20 claims
4199US11077171B2Immunotherapy against several tumors including gastrointestinal and gastric cancerIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Aug 3, 2021·18 cites·20 claims
4299US11071773B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Jul 27, 2021·8 cites·20 claims
4399US11065315B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jul 20, 2021·12 cites·20 claims
4499US11058726B2Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jul 13, 2021·4 cites·20 claims
4599US11058754B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jul 13, 2021·14 cites·24 claims
4699US11027002B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jun 8, 2021·8 cites·20 claims
4799US11001616B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted May 11, 2021·5 cites·20 claims
4899US10947294B2Peptides and combination of peptides for use in immunotherapy against various tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Mar 16, 2021·18 cites·30 claims
4999US10947293B2Peptides and combination of peptides for use in immunotherapy against various tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Mar 16, 2021·18 cites·28 claims
5099US10941181B2Immunotherapy against several tumors including neuronal and brain tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2016·Granted Mar 9, 2021·14 cites·9 claims

Showing the top 50 of 604 patent records by PatentIndex Score.

Join the waitlist — get patent alerts

Get an alert when Harpreet Singh files or is granted a new patent.

We store only your email — no account needed. See our privacy policy.

Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →